JP2012523838A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523838A5
JP2012523838A5 JP2012505990A JP2012505990A JP2012523838A5 JP 2012523838 A5 JP2012523838 A5 JP 2012523838A5 JP 2012505990 A JP2012505990 A JP 2012505990A JP 2012505990 A JP2012505990 A JP 2012505990A JP 2012523838 A5 JP2012523838 A5 JP 2012523838A5
Authority
JP
Japan
Prior art keywords
seq
sample
nos
subject
marker genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012505990A
Other languages
English (en)
Japanese (ja)
Other versions
JP5836929B2 (ja
JP2012523838A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/031528 external-priority patent/WO2010121231A1/en
Publication of JP2012523838A publication Critical patent/JP2012523838A/ja
Publication of JP2012523838A5 publication Critical patent/JP2012523838A5/ja
Application granted granted Critical
Publication of JP5836929B2 publication Critical patent/JP5836929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012505990A 2009-04-18 2010-04-17 抗cd40抗体を用いる治療に対するb細胞性リンパ腫の応答性を評価するための方法 Active JP5836929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17061509P 2009-04-18 2009-04-18
US61/170,615 2009-04-18
PCT/US2010/031528 WO2010121231A1 (en) 2009-04-18 2010-04-17 Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies

Publications (3)

Publication Number Publication Date
JP2012523838A JP2012523838A (ja) 2012-10-11
JP2012523838A5 true JP2012523838A5 (cg-RX-API-DMAC7.html) 2013-06-06
JP5836929B2 JP5836929B2 (ja) 2015-12-24

Family

ID=42358184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012505990A Active JP5836929B2 (ja) 2009-04-18 2010-04-17 抗cd40抗体を用いる治療に対するb細胞性リンパ腫の応答性を評価するための方法

Country Status (12)

Country Link
US (1) US9617600B2 (cg-RX-API-DMAC7.html)
EP (1) EP2419531B1 (cg-RX-API-DMAC7.html)
JP (1) JP5836929B2 (cg-RX-API-DMAC7.html)
KR (1) KR101787768B1 (cg-RX-API-DMAC7.html)
CN (1) CN102459639A (cg-RX-API-DMAC7.html)
AU (1) AU2010236168B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011394A8 (cg-RX-API-DMAC7.html)
CA (1) CA2758523C (cg-RX-API-DMAC7.html)
ES (1) ES2605228T3 (cg-RX-API-DMAC7.html)
IL (1) IL215707A (cg-RX-API-DMAC7.html)
MX (1) MX2011010938A (cg-RX-API-DMAC7.html)
WO (1) WO2010121231A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
ES2634254T3 (es) 2011-09-12 2017-09-27 Atrys Health, SA Métodos para el pronóstico del linfoma difuso de linfocitos B grandes
KR20210073616A (ko) 2012-08-09 2021-06-18 셀진 코포레이션 면역-관련 및 염증성 질환의 치료
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
AU2016326499A1 (en) * 2015-09-25 2018-04-12 Celgene Corporation Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP4256087A4 (en) * 2020-12-02 2024-12-04 Albert Einstein College of Medicine METHOD FOR PREDICTING PATIENT RESPONSE TO CD40-TARGETED THERAPIES
CN117092336B (zh) * 2023-06-16 2026-06-05 中国医学科学院北京协和医院 血浆n4bp1、creb1、ubap2、deaf1自身抗体标志物在弥漫大b细胞淋巴瘤预后预测中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
CA2402525A1 (en) 2000-03-31 2001-10-11 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック, インコーポレイテッド 併用療法
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗cd40モノクローナル抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2312315A1 (en) * 2005-05-18 2011-04-20 Novartis AG Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
JP5027804B2 (ja) 2005-05-26 2012-09-19 シアトル ジェネティクス,インコーポレーテッド ヒト化抗cd40抗体およびその使用方法
EP2687608B1 (en) * 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
EP1943523A2 (en) * 2005-09-16 2008-07-16 Biovator Technologies AB In vitro assay for identification of allergenic proteins
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
MX2008007140A (es) 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
US7527774B2 (en) 2005-12-22 2009-05-05 Basf Catalysts Llc Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms
US20090075272A1 (en) * 2006-01-20 2009-03-19 Hollmann C Annette Method to Identify CD40-Sensitive Cells Using Gene Expression
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
KR101620642B1 (ko) * 2007-11-07 2016-05-12 제넨테크, 인크. 항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물

Similar Documents

Publication Publication Date Title
JP2011504102A5 (cg-RX-API-DMAC7.html)
ES2905579T3 (es) Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
JP6664011B2 (ja) サンプル中のポリヌクレオチド配列のための存在量パラメータの決定
JP7157788B2 (ja) 膵・消化管神経内分泌新生物の診断のための組成物、方法およびキット
Guo et al. An enzyme-free and label-free surface plasmon resonance biosensor for ultrasensitive detection of fusion gene based on DNA self-assembly hydrogel with streptavidin encapsulation
Zeng et al. Detection of KRAS G12D point mutation level by anchor-like DNA electrochemical biosensor
JP2014509868A5 (cg-RX-API-DMAC7.html)
JP2013521763A5 (cg-RX-API-DMAC7.html)
CN103502473A (zh) 胃肠胰神经内分泌肿瘤(gep-nen)的预测
CA2735129A1 (en) Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation
JP2009526519A5 (cg-RX-API-DMAC7.html)
CN109182517A (zh) 一组用于髓母细胞瘤分子分型的基因及其应用
JPWO2018056432A1 (ja) 血液検体の溶血を検出する方法及び溶血検出用チップ
CA2795554A1 (en) Gene-expression profiling with reduced numbers of transcript measurements
Ensafi et al. A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia
JP2017509351A5 (cg-RX-API-DMAC7.html)
JPWO2020027098A1 (ja) 体液検体の品質評価方法
Scarfò et al. What does it mean I have a monoclonal B-cell lymphocytosis?: recent insights and new challenges
CN103451268B (zh) 一种检测线粒体a3243g杂合突变率的标准品、试剂盒及其检测方法
CN114032308B (zh) Fam83a、kpna2、krt6a和ldha联合作为肺腺癌生物标志物的用途
RU2011134644A (ru) Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома
JP2008518598A5 (cg-RX-API-DMAC7.html)
Zhang et al. Rapid monitoring and early warning of Phaeocystis globosa bloom based on an effective electrochemical biosensor
EP2499261A2 (en) Genes differentially expressed by cumulus cells and assays using same to identify pregnancy competent oocytes
AU2020245086A1 (en) Classification of B-Cell non-Hodgkin Lymphomas